Neurocrine biosciences honors mental health awareness month and fifth anniversary of tardive dyskinesia awareness week

States across the country declare first week of may (1-7) tardive dyskinesia awareness week to raise awareness of this burdensome and often misunderstood condition an estimated 75% of those with td have not been diagnosed and an estimated 600,000 people live with this condition in the u.s. alone san diego , may 2, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its support of mental health awareness month and commitment to raising awareness of and supporting people living with tardive dyskinesia (td) through tardive dyskinesia awareness week. td is a persistent and often irreversible movement disorder associated with prolonged use of certain mental health medicines (antipsychotics) to treat bipolar disorder, depression, schizophrenia, or schizoaffective disorder.1,2-5 this year marks the fifth consecutive year the mental health advocacy community and states across the country have recognized the first week of may (1-7) as tardive dyskinesia awareness week.
NBIX Ratings Summary
NBIX Quant Ranking